ArticleScientific reports2025
Predicting head and neck cancer response to radiotherapy with a chemokine-based model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial.Nature communications · 2026Trial
- Review
- Metabolic gene expression-based stratification and prognostic risk predictive model of head and neck squamous cell carcinoma.NPJ systems biology and applications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy resistance remains a major challenge in Head and neck squamous cell carcinoma (HNSCC) treatment. This study aimed to develop a chemokine-based model for predicting radiosensitivity in HNSCC using a retrospective analysis of 432 patients from the TCGA database. We identified a model incorporating CXCL2, CCL28, and CCR8 expression that effectively stratified patients into radiosensitive (RS) and radioresistant (RR) groups. Patients in the RS group demonstrated significantly improved overall survival (OS) with radiotherapy, whereas this prognostic advantage was not observed in the non-radiotherapy group. Notably, patients within the RS group with high PD-L1 expression exhibited even better OS and increased immune infiltration, indicating a synergistic relationship between radiosensitivity and PD-L1 expression. Further analyses revealed enrichment of immune-related pathways and higher effector immune cell abundance in the RS group, suggesting greater potential for immunotherapy response. Corroborating these findings, analysis of the GSE40020 cohort showed significant upregulation of CCL28 in patients with complete response compared to those with post-treatment failure. In vitro experiments using radiosensitive and radioresistant Tongue squamous cell carcinoma (TSCC) cell lines validated the association between chemokine gene expression and radiosensitivity. Our model provides a valuable tool for identifying HNSCC patients who may benefit from combined treatment strategies incorporating synergistic anti-tumor agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.